Pesquisar
Adagene Inc
ADAGAdicionar à lista de desejos
4.470USD
-0.310-6.49%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
211.81MValor de mercado
PerdaP/L TTM
Mais detalhes de Adagene Inc Empresa
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Informações de Adagene Inc
Código da empresaADAG
Nome da EmpresaAdagene Inc
Data de listagemFeb 09, 2021
CEOLuo (Peter)
Número de funcionários138
Tipo de títulosDepository Receipt
Fim do ano fiscalFeb 09
Endereço4F, Building C14, No. 218, Xinghu Street
CidadeSUZHOU
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísChina
Código postal- -
Telefone8651287773632
Sitehttps://www.adagene.com/
Código da empresaADAG
Data de listagemFeb 09, 2021
CEOLuo (Peter)
Executivos da empresa Adagene Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Ms. Zhou Ling
Ms. Zhou Ling
Senior Director of Human Resources
Senior Director of Human Resources
--
--
Ms. Li Yan
Ms. Li Yan
Senior Vice President of Bioinformatics and Information Technology
Senior Vice President of Bioinformatics and Information Technology
--
--
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Dr. Fangyong (Felix) Du, Ph.D.
Dr. Fangyong (Felix) Du, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Xu Jc, M.D., Ph.D.
Dr. Xu Jc, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Mr. Tam (Raymond) Man Kin
Mr. Tam (Raymond) Man Kin
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Adagene Inc?
Os cinco principais acionistas de Adagene Inc são: Dr. Peter (Peizhi) Luo, Ph.D.
Quantas instituições possuem ações da Adagene Inc (ADAG)?
Em 2026Q1, 38 instituições possuíam ações da Adagene Inc, com valor de mercado aproximado de 13.55M, representando 20.51% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2119805.00.